{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000104","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.343323+00:00","generated_at":"2026-05-31T03:40:28.586020+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer","bullets":["Dr. Will joins as CDO effective September 30, 2024.","Previously CMO at Dren Bio and VP Clinical Development at CRISPR Therapeutics.","Will lead development organization, including obe-cel for relapsed/refractory adult B-ALL.","Appointment comes as Autolus prepares to commercialize first product obe-cel."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000104","json":"https://secwatch.observer/filing/0001730463-24-000104.json","markdown":"https://secwatch.observer/filing/0001730463-24-000104.md","text":"https://secwatch.observer/filing/0001730463-24-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/0001730463-24-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/autl-20240913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:40:28.586020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}